openPR Logo
Press release

Aperture Bio seeks B Series Funding as it Completes Final FDA Submission and Prepares for Full Commercialization of its RAPID-B and empiriSTAT : Rapid ID of Bacterial Infections and Antibiotic Profiling

06-11-2019 10:07 AM CET | Health & Medicine

Press release from: Aperture Bio

Aperture Bio seeks B Series Funding as it Completes Final FDA

Responding to increased demand for its proprietary RAPID-B(TM) diagnostic platform and empiriSTAT test menu, Aperture Bio has announced its intention to seek B Series investors as it heads to full commercialization. The company is looking to enter the clinical diagnostics market, which is valued at US$168 billion and growing at a 7.3% CAGR, according to data released by Coherent Market Insights in 2015.

In a statement from Aperture’s president, David Potenza, “With growing awareness of our technology, the market’s response and demand for our innovative diagnostic platform has prompted the board’s decision to seek outside investors. With additional funding to support accelerating our timelines for full commercialization and introduction to world markets, we could begin playing a role in curbing antibiotic resistance, potentially saving lives and billions in related healthcare costs.”

The urgent need to reduce the overuse and misuse of antibiotics through empirical prescribing is at the forefront of the world’s public health agencies. Laboratory directors, hospital administrators and world health concerns are seeking technologies and strategies to address the alarming, and unnecessary, overuse of antibiotics in an effort to save lives and billions in providing treatment for the millions that could be affected:

The United Nations (U.N.’s) Interagency Coordination Group on Antimicrobial Resistance released a report in 2019 stating that “drug-resistant infections will kill 10 million people annually by 2050” and specifically calls for “more initiatives aimed at limiting unnecessary antibiotic use.”

The World Health Organization (WHO) states, “Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally. Without urgent action, we are heading for a post- antibiotic era in which common infections and minor injuries can once again kill."

The Commissioner of the Food & Drug Administration (FDA) stated that “Antimicrobial resistance is a global public health challenge. Combating antimicrobial resistance continues to be a top priority. Our aim is to reduce overuse of antimicrobial drugs and combat the rising threat of resistance.”

The Infectious Disease Society of American (IDSA) stated "Because treatment of acute uncomplicated cystitis is usually empirical, it is likely that some women will be treated with a drug that does not have in vitro activity against the uropathogen. As the population resistance prevalence of a specific agent increases, the likelihood of failure outweighs the benefits of using the drug empirically."

The overuse and misuse of antibiotics in the healthcare setting is, in great part, due to the necessity of empirical, and often “blind,” over-prescribing of antibiotics. These prescribing habits, primarily done as a defensive response on the suspicion of an infection, are often caused by known inaccuracies in screening technology and delays in actionable lab results. The unintentional consequences created by the defensive response of caregivers is coming to the forefront of community and world health officials and needs to be addressed.

With over 100 million UTIs tests performed each year and tens of millions of blood tests, the impact on reducing the need for empirical prescribing and overuse of antibiotics is a population health issue, impacting communities around the world. In 2013, the Centers for Disease Control (CDC) reported 2 million people get an antibiotic resistant infection, and at least 23,000 people die. New data, due out later this year, suggests those numbers have escalated exponentially. The costs to the U.S. healthcare system tops over $5 billion annually and is estimated to reach $100 trillion world-wide by 2050, according to amr-review.org.

The RAPID-B(TM) is poised to address these growing concerns by offering healthcare providers access to a highly accurate, low cost and fast screening technology coupled with Antibiotic Profiling. This clinically available technology could greatly reduce the need for empirical prescribing and reduce the costs of unnecessary add-on testing or further delays in treatment. In the fight against antibiotic resistance, the negative predictive value, knowing which patients do not require treatment with in minutes, could be as impactful as knowing which patient do need treatment. Providing Antibiotic Predictive Profiling (APP) with in hours helps ensure only those patients that need treatment are prescribed the most appropriate medications, greatly reducing their misuse and potential to build resistance.

The RAPID-B(TM) has completed over two years of clinical evaluations and is working on expanded indications for blood and cerebral spinal fluid (meningitis). Additionally, Aperture Bio is in collaboration with Nuview Life Sciences to fully automate their prostate cancer screening assay on the RAPID-B(TM) platform. For uncomplicated UTIs the platform was able to achieve 98% sensitivity and 89% specificity, out-performing other known technologies.

To accomplish these fast and accurate results, the RAPID-B(TM) utilizes highly customized and fully robotic next-generation flow cytometric technology (nFC), coupled with proprietary chemistry and customized platting. Through these proprietary and patent pending methodologies, the system enumerates only viable bacteria and white blood cells (for urine) within minutes and provides Antibiotic Predictive Profiling (APP) within hours.

In a follow-up statement from Aperture’s president, “There is a real need for technology that can help address overuse and misuse of antibiotics throughout the world. We believe our first-of-its-kind, disruptive technology can play a role in helping curb the proliferation in antibiotic resistance and could redefine how infections are identified and treated …. This technology is ready to make a difference and needs to be in the hands of healthcare providers today.”

David Potenza
President
1-214-707-8710
dpotenza@aperturebio.com
20 Winter Sports Land
Williston, VT 05495

About Aperture Bio – Aperture Bio is a privately held laboratory diagnostic company whose focus is to bring emerging technologies to market aimed at addressing antibiotic resistance and other world health issues. The company is currently seeking B Series investors to further expand its product offering and the commercialization of its proprietary RAPID-BTM platform. For investment opportunities, please contact Mr. David Potenza dpotenza@aperturebio.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aperture Bio seeks B Series Funding as it Completes Final FDA Submission and Prepares for Full Commercialization of its RAPID-B and empiriSTAT : Rapid ID of Bacterial Infections and Antibiotic Profiling here

News-ID: 1770279 • Views: 458

More Releases from Aperture Bio

Aperture Bio to Begin Accepting Pre-orders for its RAPIB-B(TM) Quantitative Micr …
(Dallas, TX – 6/24/19) - www.Aperturebio.com. In response to the growing demand for advanced diagnostic tools to aid in the fight of overused and misused antibiotics, Aperture Bio has begun accepting pre-orders of its RAPID-B(TM) and its empiriSTAT menu of diagnostic tests. In a statement from Aperture Bio’s president, David Potenza, “With world health agencies calling for increased action to combat resistance, and no new antibiotics on the horizon, healthcare
Aperture Bio & NuView Life Sciences Sign Definitive Agreement to Investigate Exp …
(Dallas, TX/Salt Lake City, UT) – In a joint press release, Aperture Bio and NuView Life Sciences have entered into an agreement to begin collaborative investigational studies to assess NuView’s proprietary NV-VPAC1(TM) urogenital cancer test utilizing Aperture Bio’s RAPID-B(TM) proprietary screening platform. Aperture Bio has developed a proprietary diagnostic platform, the RAPID-BTM, designed for rapid and accurate detection of bacterial infections found in both urine and blood specimens. The
Aperture Bio Invited to Present at Antimicrobial Resistance World Congress
(Dallas, TX – 5/13/19) - www.Aperturebio.com – Aperture Bio announces it has been invited to present at the WORLD ANTIMICROBIAL RESISTENCE CONGRESS on November 7-8 in Washington, D.C. Aperture will present its RAPID-BTM in vitro diagnostic platform for the rapid detection of bacterial infections and antibiotic profiling, which could assist caregivers reduce the need for empirical overprescribing of antibiotics. The event will host some +600 attendees from over
Aperture Bio Ready to Introduce its Diagnostic Platform to Combat Antibiotic Res …
(Dallas, TX - 4/1/19) - www.Aperturebio.com. After more than two-years of clinical evaluations conducted at Northwestern, Washington University and University of Vermont Medical Center, Aperture Bio has announced it is ready to introduce its proprietary testing platform, the RAPID-BTM, and the empiriSTAT-UTI, for the rapid detection of uncomplicated urinary tract infections (UTIs) and antibiotic profiling performed within hours. Utilizing highly customized and fully robotic next-gen flow cytometric technology (nFC), coupled

All 5 Releases


More Releases for Series

Appu Series - Watch. Learn. Grow.
The memory of those with the gift of sight is graphic. Why not incorporate that in learning is Appu Series’ take. We all know what a picture is worth. Appu Series cashes in on a repository of images. All serving the purpose of education and riveting entertainment. What cannot be sketched out on a blackboard or delivered through an hour of lecture can be squeezed into a few minutes of visuals, audios
First TV Series in Latin
The turbulent adventures of the Roman restaurant owner Barrelius and his Germanic family in the ancient Roman Empire are the focus of the planned new television series MY MANIAC MANSIO. Supporters of the recently launched project crowdfunding for the presentation of a MY MANIAC MANSIO trailer on major TV stations and international streaming services can not only secure "ancient" rewards, but also participate in the production as technical staff or even
Home Retail Series: Window Dressings
Summary The UK window dressings market is forecast to slow to 1.4% growth in 2016, underperforming the homewares sector, due to weakening consumer confidence, a slower housing market in H2 and economic instability following the Brexit vote, with shoppers delaying larger ticket homewares purchases, such as curtains and shutters. Key Findings – “Dunelm is the dominant leader of the window dressings market, exploiting its specialist credentials to hold significant destination appeal in the
Test Series for Gate
As the market is not only based on talent any more but demands smart brains scoring stupendous. As just being a graduate from a simple or less renowned college does not make you stand in the market that demands highly educated and professional citizens people are switching themselves for higher education to reputed university and the entrance gate for reputed colleges are only through exams like GATE. People are spending
Home Retail Series: Laundry & Cleaning
Summary The laundry & cleaning market is expected to grow 1.6% in 2016, the highest rise in over five years. With growth heavily reliant on replacement purchases and sales of everyday household essentials, the market has been relatively stable, while larger ticket items, such as kitchen bins and airers, have also benefited from the housing market recovery post downturn though this will ease as housing transactions slow. Key Findings "The grocers will continue
Cisco 7200 Series Routers
Nov 30, 2011- Cisco 7200 Series Routers are modular routers that support a multitude of performance, service and density needs. The 7200 router is the hardware industry’s most widely deployed universal services aggregation router for enterprise and service provider edge applications. History 7200 routers were first shipped several years ago, replacing the now defunct 7010, which had had its heyday in the 1990s. The first 7200 models were somewhat average in their